is listed at the Spotlight Stock Market since 2012.
Our ticker: RESP
Redeye AB
Equity Analyst: Arvid Necander
arvid.necander@redeye.se
Latest research on Respiratorius https://www.redeye.se/company/respiratorius
Respiratorius AB (publ) develops candidate drugs with the goal of launching drugs to treat aggressive lymphoma (cancer).
Respiratorius AB
Medicon Village
Scheeletorget 1, 223 81 Lund, Sweden
info@respiratorius.com
+46 70 922 41 40
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
